NasdaqGM:CRSPBiotechs
Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative?
In recent days, attention on CRISPR Therapeutics has intensified ahead of its March-quarter earnings report, as analysts expect higher revenue and earnings alongside evolving estimates.
Investor focus is also being shaped by rising sales of Casgevy, the gene-editing therapy co-developed with Vertex Pharmaceuticals, which is showing sequential launch momentum.
We’ll now examine how expectations for stronger quarterly results and early Casgevy uptake could influence CRISPR Therapeutics’...